Literature DB >> 34985678

Cure and Long-Term Remission Strategies.

Luisa Mori1, Susana T Valente2.   

Abstract

The majority of virally suppressed individuals will experience rapid viral rebound upon antiretroviral therapy (ART) interruption, providing a strong rationale for the development of cure strategies. Moreover, despite ART virological control, HIV infection is still associated with chronic immune activation, inflammation, comorbidities, and accelerated aging. These effects are believed to be due, in part, to low-grade persistent transcription and trickling production of viral proteins from the pool of latent proviruses constituting the viral reservoir. In recent years there has been an increasing interest in developing what has been termed a functional cure for HIV. This approach entails the long-term, durable control of viral expression in the absence of therapy, preventing disease progression and transmission, despite the presence of detectable integrated proviruses. One such strategy, the block-and-lock approach for a functional cure, proposes the epigenetic silencing of proviral expression, locking the virus in a profound latent state, from which reactivation is very unlikely. The proof-of-concept for this approach was demonstrated with the use of a specific small molecule targeting HIV transcription. Here we review the principles behind the block-and-lock approach and some of the additional strategies proposed to silence HIV expression.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Block-and-lock; Epigenetic silencing; HIV functional cure; HIV transcription; Tat inhibitors

Mesh:

Year:  2022        PMID: 34985678     DOI: 10.1007/978-1-0716-1871-4_26

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  263 in total

1.  Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection.

Authors:  Laurent Hocqueloux; Thierry Prazuck; Véronique Avettand-Fenoel; Alain Lafeuillade; Bernard Cardon; Jean-Paul Viard; Christine Rouzioux
Journal:  AIDS       Date:  2010-06-19       Impact factor: 4.177

Review 2.  Post-Treatment Controllers: Role in HIV "Cure" Research.

Authors:  Leslie R Cockerham; Hiroyu Hatano; Steven G Deeks
Journal:  Curr HIV/AIDS Rep       Date:  2016-02       Impact factor: 5.071

Review 3.  Unravelling the mechanisms of durable control of HIV-1.

Authors:  Bruce D Walker; Xu G Yu
Journal:  Nat Rev Immunol       Date:  2013-07       Impact factor: 53.106

4.  The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies.

Authors:  Golnaz Namazi; Jesse M Fajnzylber; Evgenia Aga; Ronald J Bosch; Edward P Acosta; Radwa Sharaf; Wendy Hartogensis; Jeffrey M Jacobson; Elizabeth Connick; Paul Volberding; Daniel Skiest; David Margolis; Michael C Sneller; Susan J Little; Sara Gianella; Davey M Smith; Daniel R Kuritzkes; Roy M Gulick; John W Mellors; Vikram Mehraj; Rajesh T Gandhi; Ronald Mitsuyasu; Robert T Schooley; Keith Henry; Pablo Tebas; Steven G Deeks; Tae-Wook Chun; Ann C Collier; Jean-Pierre Routy; Frederick M Hecht; Bruce D Walker; Jonathan Z Li
Journal:  J Infect Dis       Date:  2018-11-05       Impact factor: 5.226

Review 5.  Epidemiology and clinical characteristics of elite controllers.

Authors:  Jason F Okulicz; Olivier Lambotte
Journal:  Curr Opin HIV AIDS       Date:  2011-05       Impact factor: 4.283

6.  HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.

Authors:  Cécile Goujard; Isabelle Girault; Christine Rouzioux; Camille Lécuroux; Christiane Deveau; Marie-Laure Chaix; Christine Jacomet; Amel Talamali; Jean-François Delfraissy; Alain Venet; Laurence Meyer; Martine Sinet
Journal:  Antivir Ther       Date:  2012-08-06

7.  Prolonged control of replication-competent dual- tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy.

Authors:  Maria Salgado; S Alireza Rabi; Karen A O'Connell; Robert W Buckheit; Justin R Bailey; Amina A Chaudhry; Autumn R Breaud; Mark A Marzinke; William Clarke; Joseph B Margolick; Robert F Siliciano; Joel N Blankson
Journal:  Retrovirology       Date:  2011-12-05       Impact factor: 4.602

8.  A child with perinatal HIV infection and long-term sustained virological control following antiretroviral treatment cessation.

Authors:  Avy Violari; Mark F Cotton; Louise Kuhn; Diana B Schramm; Maria Paximadis; Shayne Loubser; Sharon Shalekoff; Bianca Da Costa Dias; Kennedy Otwombe; Afaaf Liberty; James McIntyre; Abdel Babiker; Diana Gibb; Caroline T Tiemessen
Journal:  Nat Commun       Date:  2019-01-24       Impact factor: 14.919

Review 9.  Learning From the Exceptions: HIV Remission in Post-treatment Controllers.

Authors:  Behzad Etemad; Elmira Esmaeilzadeh; Jonathan Z Li
Journal:  Front Immunol       Date:  2019-07-24       Impact factor: 7.561

10.  Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study.

Authors:  Asier Sáez-Cirión; Charline Bacchus; Laurent Hocqueloux; Véronique Avettand-Fenoel; Isabelle Girault; Camille Lecuroux; Valerie Potard; Pierre Versmisse; Adeline Melard; Thierry Prazuck; Benjamin Descours; Julien Guergnon; Jean-Paul Viard; Faroudy Boufassa; Olivier Lambotte; Cécile Goujard; Laurence Meyer; Dominique Costagliola; Alain Venet; Gianfranco Pancino; Brigitte Autran; Christine Rouzioux
Journal:  PLoS Pathog       Date:  2013-03-14       Impact factor: 6.823

View more
  1 in total

Review 1.  Host Restriction Factors Modulating HIV Latency and Replication in Macrophages.

Authors:  Isabel Pagani; Pietro Demela; Silvia Ghezzi; Elisa Vicenzi; Massimo Pizzato; Guido Poli
Journal:  Int J Mol Sci       Date:  2022-03-11       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.